ClinicalTrials.gg
CompletedNCT01323660COPDUpdated Feb 15, 2018Results posted

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

A Phase 3 interventional study of GSK573719/GW642444 125/25 and GSK573719/GW642444 62.5/25 in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 53 sites in 7 countries. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-02-15.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
40 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.

Enrollment
17th of 43
307 · median 131
Started
2011
with 7 others
Phase 3
14 of 43
none open now
Registered
10th of 43
by date
Lead sponsor
35 of 43
GlaxoSmithKline

Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 3, and was the 10th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About GSK573719

GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI).

Read the detailed description

Expiratory airflow limitation is the most obvious physiological change associated with chronic obstructive pulmonary disease (COPD). A consequence of airflow limitation is gas trapping as expiration becomes flow limited. This may occur at rest with more severe airway obstruction and is most evident during exercise as lung emptying is reduced and increased ventilation does not allow full expiration. This increased gas trapping or hyperinflation is the cause of much of the increased work of breathing, dyspnea, and exercise intolerance in subjects with COPD (O'Donnell 1997; O'Donnell, 1993). Spirometric measurement of airflow limitation, particularly as assessed by forced expiratory volume in one second (FEV1), is commonly used for the diagnosis of and assessment of response to pharmacotherapeutic intervention in COPD. However, changes in FEV1 may not fully predict symptomatic responses and alternative measures of lung hyperinflation such as exercise tolerance and exertional dyspnea may be more sensitive to therapeutic intervention and/or more clinically relevant than FEV1 [O'Donnell1999; Bauerle, 1998; O'Donnell, 1998; Officer, 1998]. GSK573719/GW642444 Inhalation Powder, a combination of the long-acting muscarinic antagonist (LAMA) bronchodilator GSK573719 and the long-acting beta2-agonist (LABA) bronchodilator GW642444, is in development for the maintenance treatment of airflow obstruction associated with COPD. Development of this product is supported by studies showing improvement in lung function with similar safety when use of combinations of long-acting bronchodilators with different mechanisms of action are compared with single bronchodilator therapy [van Noord 2005; van Noord van Noord 2006; Tashkin 2008]. Previous studies have demonstrated that treatment with short- and long-acting bronchodilators including ipratropium, tiotropium, and salmeterol reduces resting lung hyperinflation as measured by functional residual capacity (FRC), residual volume (RV), and inspiratory capacity (IC), with associated improvements in exercise endurance time and exertional dyspnoea in subjects with COPD [Ayers, 2001; O'Donnell 1998; O'Donnell 2004; Pepin 2005; Pepin 2007; Ramirez-Venegas 1997]. However, the effect of combined LAMA/LABA therapy on these measures is not well characterized.

This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI) Approximately 312 subjects with moderate/severe chronic obstructive pulmonary disease (COPD) will be randomised in order to achieve 208 subjects completing both treatment periods of 3 months.. There will be a total of 12 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 12 to 21 day run-in period followed by two 12-week treatment periods that are separated by a 14 day wash-out. Clinic visits will be conducted at Screening (Visit 1), twice during the run-in period (Visits 2 and 3), at randomization (Visit 4) and three times during the first treatment period, on Treatment Day 2 (Visit 5) and at 6 and 12 weeks (Visits 6 and 7 respectively). During the washout period of 14 days there will be 2 clinic visits (Visits 8 and 9). During the second treatment period there will be 3 clinic visits, on Treatment Day 2 (Visit 10) and at 6 and 12 weeks (Visits 11 and 12 respectively). A Safety Follow-Up assessment (Visit 13) to record adverse events will be conducted by telephone 7 days after the end of the second treatment period or early withdrawal. Efficacy measurements will include pre and post dose FEV1, lung volume measurements and exercise endurance time measured using the endurance shuttle walking test (ESWT). Safety and tolerability will be assessed by collection of adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), clinical laboratory tests and incidence of COPD exacerbations. Dyspnea will be assessed using the Exercise Dyspnea Scale (EDS), a patient-reported outcome. Blood samples will also be collected for potential pharmacogenetics analysis

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient.
  • : A signed and dated written informed consent prior to study participation.
  • Age: 40 years of age or older at Visit 1.
  • Gender: Male or female subjects.
  • Diagnosis: An established clinical history of in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]
  • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years
  • Severity of Disease: A post-albuterol/salbutamol /FVC ratio of 0.70 and a post-albuterol/salbutamol FEV1 of >35% and \<70% of predicted normal
  • Dyspnea: A score of ≥2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1
  • Resting Lung Volumes: A resting FRC of ≥120% of predicted normal FRC at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: A current diagnosis of asthma.
  • Other Respiratory Disorders: Known respiratory disorders other than including but not limited to alpha-1 antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease. Allergic rhinitis is not exclusionary.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \< 5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. Any physical or mental abnormality which would affect the patient carrying out exercise tests including peripheral vascular disease should be excluded at the investigators discretion.
  • Chest X-Ray: A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Visit 1 if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For subjects in Germany, if a chest X-ray (or CT scan) is not available in the 6 months prior to Visit 1 the subject will not be eligible for the study.
  • : A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
  • Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
  • 12-Lead : An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, including the presence of a paced rhythm on a 12-lead electrocardiogram (ECG) which causes the underlying rhythm and ECG to be obscured. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility.
  • Screening Labs: Significantly abnormal finding from clinical chemistry and hematology tests at Visit 1.
  • Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
  • Medications prior to Screening, including depot,oral , combinations of LABA/ICS, LABA, PDE4 inhibitors.
  • Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., \<12 hours per day) is not exclusionary.
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    GSK573719/GW642444 125/25

    125mcg/25mcg nDPI

    Drug: GSK573719 125 · Drug: GW642444 25 · Device: placebo

  • Experimental
    GSK573719/GW642444 62.5/25

    62.5mcg/25mcg nDPI

    Drug: GSK573719 62.5 · Drug: GW642444 25 · Device: placebo

  • Experimental
    GSK573719/ 125

    125mcg nDPI

    Drug: GSK573719/GW642444 125/25 · Device: placebo

  • Experimental
    GSK573719 62.5

    62.5mcg nDPI

    Drug: GSK573719/GW642444 62.5/25 · Device: placebo

  • Experimental
    GW642444 25

    25mcg nDPI

    Drug: GSK573719/GW642444 125/25 · Drug: GSK573719/GW642444 62.5/25 · Device: placebo

  • Placebo comparator
    Placebo

    Plb nDPI

    Drug: GSK573719/GW642444 125/25 · Drug: GSK573719/GW642444 62.5/25 · Drug: GSK573719 125 · Drug: GSK573719 62.5 · Drug: GW642444 25

Interventions

  • DrugGSK573719/GW642444 125/25

    125mcg/ 25mcg QID (Once daily , inhaled)

  • DrugGSK573719/GW642444 62.5/25

    62.5mcg/25mcg QID

  • 125mcg QID

  • 62.5mcg QID

  • 25mcg QID

  • Deviceplacebo

    Comparator QID

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

    Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.

    Time frame: Week 12 of each treatment period (up to Study Week 30)

  2. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.

    Time frame: Week 12 of each treatment period (up to Study Week 30)

Secondary outcomes

  1. Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

    Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

    Time frame: Week 12 of each treatment period (up to Study Week 30)

  2. Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

    Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

    Time frame: Week 12 of each treatment period (up to Study Week 30)

  3. Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

    Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 1.

    Time frame: Week 12 of each treatment period (up to Study Week 30)

  4. Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period

    FEVI is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.

    Time frame: Week 12 of each treatment period (up to Study Week 30)

07

Results

Posted Apr 11, 2014

Participant flow

Participants (par.) who were eligible completed a 12- to 21-day Run-in Period followed by two 12-week treatment (trt) periods.

Treatment Period 1 (12 Weeks)
Participant flow — Treatment Period 1 (12 Weeks)
MilestonePlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC 125/25 µg QD
Started842224367170
Completed652119316161
Not completed19155109
Withdrew: Adverse event611334
Withdrew: Lack of efficacy602013
Withdrew: Protocol violation201112
Withdrew: Met protocol-defined stopping criteria000010
Withdrew: Lost to follow-up000010
Withdrew: Withdrawal by subject501130
Washout Period (14 Days)
Participant flow — Washout Period (14 Days)
MilestonePlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC 125/25 µg QD
Started652119316161
Completed652118285859
Not completed001332
Withdrew: Adverse event000010
Withdrew: Lack of efficacy001322
Treatment Period 2 (12 Weeks)
Participant flow — Treatment Period 2 (12 Weeks)
MilestonePlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC 125/25 µg QD
Started671817285958
Completed551714255551
Not completed1213347
Withdrew: Adverse event100112
Withdrew: Lack of efficacy902213
Withdrew: Study closed/terminated000001
Withdrew: Lost to follow-up100001
Withdrew: Withdrawal by subject111020

Outcome measures

PrimaryChange From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.

Time frame:
Week 12 of each treatment period (up to Study Week 30)
Reported as:
Least squares mean · Seconds
Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period
SecondsPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period0.1 ± 16.6625.1 ± 30.1874.8 ± 31.5830.7 ± 24.7969.5 ± 17.0965.9 ± 17.48
Statistical analysis
  • Placebo vs UMEC 62.5 µg QD · Mixed Models Analysis · p = 0.456 (Nominal p-value) · Least squares mean difference: 25.0 · 95% CI -41.0 to 91.0Least square mean change difference=UMEC 62.5 µg minus Placebo.
  • Placebo vs UMEC 125 µg QD · Mixed Models Analysis · p = 0.033 (Nominal p-value) · Least squares mean difference: 74.7 · 95% CI 6.0 to 143.4Least square mean change difference=UMEC 125 µg minus Placebo.
  • Placebo vs VI 25 µg QD · Mixed Models Analysis · p = 0.295 (Nominal p-value) · Least squares mean difference: 30.6 · 95% CI -26.8 to 88.0Least square mean change difference=VI 25 µg minus Placebo.
  • UMEC 62.5 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = 0.188 (Nominal p-value) · Least squares mean difference: 44.4 · 95% CI -21.8 to 110.6Least square mean change difference=UMEC/VI 62.5/25 µg minus UMEC 62.5 µg.
  • VI 25 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = 0.187 (Nominal p-value) · Least squares mean difference: 38.8 · 95% CI -18.9 to 96.5Least square mean change difference=UMEC/VI 62.5/25 µg minus VI 25 µg.
  • UMEC 125 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.801 (Nominal p-value) · Least squares mean difference: -8.9 · 95% CI -77.8 to 60.1Least square mean change difference=UMEC/VI 125/25 µg minus UMEC 125 µg
  • VI 25 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.233 (Nominal p-value) · Least squares mean difference: 35.2 · 95% CI -22.7 to 93.1Least square mean change difference=UMEC/VI 125/25 µg minus VI 25 µg.
  • Placebo vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = 0.003 · Least squares mean difference: 69.4 · 95% CI 24.5 to 114.4Least square mean change difference=UMEC/VI 62.5/25 µg minus Placebo.
  • Placebo vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.005 · Least squares mean difference: 65.8 · 95% CI 20.3 to 111.3Least square mean change difference=UMEC/VI 125/25 µg minus Placebo.
PrimaryChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.

Time frame:
Week 12 of each treatment period (up to Study Week 30)
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period-0.043 ± 0.01560.101 ± 0.02670.212 ± 0.02870.069 ± 0.02220.200 ± 0.01560.218 ± 0.0159
Statistical analysis
  • Placebo vs UMEC 62.5 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.144 · 95% CI 0.086 to 0.203Least square mean change difference=UMEC 62.5 µg minus Placebo.
  • Placebo vs UMEC 125 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.255 · 95% CI 0.193 to 0.318Least square mean change difference=UMEC 125 µg minus Placebo.
  • Placebo vs VI 25 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.112 · 95% CI 0.061 to 0.163Least square mean change difference=VI 25 µg minus Placebo.
  • UMEC 62.5 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.099 · 95% CI 0.041 to 0.157Least square mean change difference=UMEC/VI 62.5/25 µg minus UMEC 62.5 µg.
  • VI 25 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.132 · 95% CI 0.081 to 0.183Least square mean change difference=UMEC/VI 62.5/25 µg minus VI 25 µg.
  • UMEC 125 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.849 · Least squares mean difference: 0.006 · 95% CI -0.055 to 0.067Least square mean change difference=UMEC/VI 125/25 µg minus UMEC 125 µg.
  • VI 25 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.150 · 95% CI 0.098 to 0.201Least square mean change difference=UMEC/VI 125/25 µg minus VI 25 µg.
  • Placebo vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.243 · 95% CI 0.202 to 0.284Least square mean change difference=UMEC/VI 62.5/25 µg minus Placebo.
  • Placebo vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.261 · 95% CI 0.220 to 0.303Least square mean change difference=UMEC/VI 125/25 µg minus Placebo.
SecondaryChange From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

Time frame:
Week 12 of each treatment period (up to Study Week 30)
Reported as:
Least squares mean · Liters
Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Trough-0.021 ± 0.02710.077 ± 0.04710.216 ± 0.05050.081 ± 0.03910.216 ± 0.02740.204 ± 0.0281
3-hours post-dose-0.021 ± 0.02730.155 ± 0.04650.208 ± 0.04980.156 ± 0.03890.295 ± 0.02760.312 ± 0.0283
SecondaryChange From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

Time frame:
Week 12 of each treatment period (up to Study Week 30)
Reported as:
Least squares mean · Liters
Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Trough-0.083 ± 0.0460-0.200 ± 0.0804-0.263 ± 0.0862-0.218 ± 0.0666-0.434 ± 0.0469-0.333 ± 0.0480
3-hours post-dose-0.094 ± 0.0461-0.315 ± 0.0786-0.405 ± 0.0836-0.431 ± 0.0654-0.616 ± 0.0471-0.503 ± 0.0480
SecondaryChange From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 1.

Time frame:
Week 12 of each treatment period (up to Study Week 30)
Reported as:
Least squares mean · Liters
Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Trough-0.049 ± 0.0491-0.266 ± 0.0847-0.289 ± 0.0909-0.291 ± 0.0705-0.516 ± 0.0500-0.421 ± 0.0511
3-hours post-dose-0.071 ± 0.0495-0.451 ± 0.0855-0.534 ± 0.0911-0.483 ± 0.0711-0.714 ± 0.0505-0.566 ± 0.0516
SecondaryChange From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period

FEVI is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.

Time frame:
Week 12 of each treatment period (up to Study Week 30)
Reported as:
Least squares mean · Liters
Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period-0.019 ± 0.01750.168 ± 0.02960.215 ± 0.03170.143 ± 0.02460.297 ± 0.01750.343 ± 0.0179

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs), defined as those events occuring while participants were on treatment up until one day after the last dose (up to Week 33), are reported.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/151 (2.6%)31/151 (20.5%)
UMEC 62.5 µg QD—1/40 (2.5%)5/40 (12.5%)
UMEC 125 µg QD—1/41 (2.4%)14/41 (34.1%)
VI 25 µg QD—2/64 (3.1%)12/64 (18.8%)
UMEC/VI 62.5/25 µg QD—3/130 (2.3%)20/130 (15.4%)
UMEC/VI 125/25 µg QD—5/128 (3.9%)18/128 (14.1%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1511/400/410/640/1300/128
Deep vein thrombosisVascular disorders0/1511/400/410/640/1300/128
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1510/401/410/640/1300/128
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1510/400/411/640/1300/128
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1510/400/410/640/1302/128
Leukocytoclastic vasculitisSkin and subcutaneous tissue disorders0/1510/400/411/640/1300/128
CellulitisInfections and infestations0/1510/400/410/640/1301/128
Subcutaneous abscessInfections and infestations0/1510/400/410/640/1301/128
Musculoskeletal painMusculoskeletal and connective tissue disorders0/1510/400/410/640/1301/128
Chest painGeneral disorders0/1510/400/410/640/1301/128
Most frequent other events
Most frequent other events
EventPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
NasopharyngitisInfections and infestations10/1514/404/411/648/1302/128
HeadacheRespiratory, thoracic and mediastinal disorders8/1511/404/411/643/1306/128
SinusitisInfections and infestations3/1510/402/413/642/1300/128
ToothacheGastrointestinal disorders1/1510/402/410/641/1300/128
ArthralgiaMusculoskeletal and connective tissue disorders2/1511/401/410/646/1300/128
DyspnoeaGastrointestinal disorders6/1510/401/411/640/1301/128
CoughRespiratory, thoracic and mediastinal disorders3/1510/401/412/642/1305/128
Back painMusculoskeletal and connective tissue disorders5/1510/401/412/640/1302/128
Upper respiratory tract infectionInfections and infestations1/1510/400/412/643/1303/128
Musculoskeletal painMusculoskeletal and connective tissue disorders0/1510/401/412/640/1300/128

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Study Treatments
Mean62.6 ± 7.88
Sex: Female, Male
Sex: Female, Male(Participants)All Study Treatments
Female139
Male168
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Study Treatments
African American/African Heritage6
American Indian or Alaska Native1
Asian - South East Asian Heritage1
White - White/Caucasian/European Heritage298
Mixed Race1
08

Study locations

53 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Torrance, California 90505, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80528, United States
  • GSK Investigational Site
    Hartford, Connecticut 06105, United States
  • GSK Investigational Site
    Brandon, Florida 33511, United States
  • GSK Investigational Site
    Austell, Georgia 30106, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30046, United States
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
  • GSK Investigational Site
    Livonia, Michigan 48152, United States
  • GSK Investigational Site
    Saint Charles, Missouri 63301, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87108, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Austin, Texas 78758, United States
  • GSK Investigational Site
    The Woodlands, Texas 77380, United States
  • GSK Investigational Site
    Richmond, Virginia 23225, United States
  • GSK Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • GSK Investigational Site
    Toronto, Ontario M3H 5S4, Canada
  • GSK Investigational Site
    Toronto, Ontario M5T 3A9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2W 1T8, Canada
  • GSK Investigational Site
    Quebec, G1V 4G5, Canada
  • GSK Investigational Site
    Hradec Kralove, 500 05, Czechia
  • GSK Investigational Site
    Karlovy Vary, 360 09, Czechia
  • GSK Investigational Site
    Ostrava - Poruba, 70868, Czechia
  • GSK Investigational Site
    Praha 4, 14059, Czechia
  • GSK Investigational Site
    Praha 4, 14800, Czechia
  • GSK Investigational Site
    Praha 4, Czechia
  • GSK Investigational Site
    Teplice, 415 10, Czechia
  • GSK Investigational Site
    Aarhus C, 8000, Denmark
  • GSK Investigational Site
    Hvidovre, 2650, Denmark
  • GSK Investigational Site
    Kobenhavn NV, 2400, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    George, Eastern Cape 6529, South Africa
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Gatesville, 7764, South Africa
  • GSK Investigational Site
    Groenkloof, 0181, South Africa
  • GSK Investigational Site
    Mowbray, 7700, South Africa
  • GSK Investigational Site
    Panorama, 7500, South Africa
  • GSK Investigational Site
    Donetsk, 83003, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 03038, Ukraine
  • GSK Investigational Site
    Kyiv, 03115, Ukraine
  • GSK Investigational Site
    Leicester, Leicestershire LE3 9QP, United Kingdom
  • GSK Investigational Site
    Northwood, Middlesex HA6 2RN, United Kingdom
  • GSK Investigational Site
    Birmingham, B9 5SS, United Kingdom
  • GSK Investigational Site
    Bradford, BD9 6RJ, United Kingdom
  • GSK Investigational Site
    Cottingham, East Yorkshire, HU16 5JQ, United Kingdom
  • GSK Investigational Site
    Doncaster, DN2 5LT, United Kingdom
  • GSK Investigational Site
    Glasgow, G11 6NT, United Kingdom
  • GSK Investigational Site
    Somerset, TA1 5DA, United Kingdom
  • GSK Investigational Site
    Wolverhampton, WV10 00B, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 9 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2011
First posted
Mar 25, 2011
Start
Mar 16, 2011
Primary completionActual
Jul 1, 2012
CompletionActual
Jul 16, 2012
Results delay requested
Jan 10, 2013
Results first posted
Apr 11, 2014
Last update
Feb 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01323660
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 25, 2011
Start date
Mar 16, 2011
Primary completion
Jul 1, 2012
Completion
Jul 16, 2012
Results posted
Apr 11, 2014
Last update
Feb 15, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK573719 · Vilanterol

Start the discussion